Could this be the new benchmark for anti-wrinkle treatments?

Anti-wrinkle treatment loyalists have long been hooked on its skin smoothing and line-reducing properties, scheduling regular, rolling appointments to maintain a youthful visage. However, as time goes on, it seems that more frequent treatments are required, or higher doses are needed, and the efficacy is perhaps not as strong as it once was. This is often due to a phenomenon colloquially called ‘Botulinum Resistance’ — a developed resistance to the effects of botulinum toxin, the active ingredient in anti-wrinkle injections, which can (unfortunately) develop over time.

With this in mind, brands have begun seeking alternate injectable solutions that may reduce the risk of resistance, and one such treatment, now available in New Zealand, is XEOMIN®. This burgeoning anti-wrinkle treatment is a type of botulinum toxin that is free of complexing proteins and has a lower risk of triggering an immune response (1,4), meaning it’s more likely to go the distance.

Feel like you're missing out? Be the first to know about what's new & noteworthy.
Sign up to our free EDM subscription today.
Please enable JavaScript in your browser to complete this form.

So, what makes XEOMIN different to other botulinum toxins when it comes to botulinum toxin resistance?

There are different types and brands of botulinum toxin products, which all act in the same way, however, may vary in their potency and their level of non-essential proteins such as complexing proteins and other bacterial components.4

The ‘father’ of XEOMIN® Dr Jürgen Frevert, a biochemist with over 30 years of toxin research, had a desire to create a pure neurotoxin so that patients need only receive the pure active ingredient to achieve desired results.5

Over a decade of research produced the first purified botulinum toxin free from complexing proteins. XEOMIN® is the first anti- wrinkle toxin injectable that undergoes an additional purification step in the manufacturing process, eliminating complexing proteins leaving only pure active botulinum toxin.5

Being free of complexing proteins and other bacterial components is the reason why XEOMIN® has a low risk of an immune response leading to botulinum toxin neutralising antibodies, with no known case reports of resistance attributed to XEOMIN® when used for aesthetic purposes.1

And what is the difference between botulinum toxin and dermal fillers?

Botulinum toxin and dermal fillers are both cosmetic injectables that can improve the appearance of the face, but they work in different ways.2,6

Botulinum toxin works by relaxing the muscles that cause dynamic wrinkles which occur from muscle movement, such as frown lines, forehead lines, and crow’s feet.4,7

Dermal fillers add volume and plumpness to the skin, filling in static wrinkles which occur for many reasons such as thinning skin or loss of elasticity. These wrinkles include nasolabial folds, marionette lines, and lip lines.7

Both botulinum toxin and dermal fillers can be used together or separately, depending on the individual needs of a person.6

Learn more about XEOMIN®, where to find it, and its efficacy here.

1. Ho WWS, Albrecht P, Calderon PE, et al. Emerging Trends in Botulinum Neurotoxin A Resistance: An International Multidisciplinary Review and Consensus. Plast Reconstr Surg Glob Open. 2022 Jun 20;10(6):e4407.
2. XEOMIN. Consumer Medicine Information. 11 July 2023
3. Ho WWS, Chan L, Corduff N, et al. Addressing the Real-World Challenges of Immunoresistance to Botulinum Neurotoxin A in Aesthetic Practice: Insights and Recommendations from a Panel Discussion in Hong Kong. Toxins (Basel). 2023 Jul 12;15(7):456.
4. XEOMIN. Healthcare Logistics. Data Sheet. 21 May 2021
5. Kerscher M, Wanitphakdeedecha R, Trindade de Almeida A, Maas C, Frevert J. IncobotulinumtoxinA: A Highly Purified and Precisely Manufactured Botulinum Neurotoxin Type A. J Drugs Dermatol. 2019 Jan 1;18(1):52-57.
6. Sundaram H, Liew S, Signorini M, et al. Global Aesthetics Consensus: Hyaluronic Acid Fillers and Botulinum Toxin Type A-Recommendations for Combined Treatment and Optimizing Outcomes in Diverse Patient Populations. Plast Reconstr Surg. 2016 May;137(5):1410-1423.
7. Peng JH, Peng HP. Cheek wrinkles revisited: Etiological classifications and nonsurgical treatment options. J Cosmet Dermatol. 2023 Jun;22(6):1733-1738.

Xeomin® (Incobotulinumtoxin A) 50, 100 Units is a Prescription Medicine. Indications: In adults, for the treatment of cervical dystonia; blepharospasm; spasticity of the upper limb; upper facial lines: glabellar frown lines, lateral periorbital lines (crow’s feet), horizontal forehead lines. Xeomin® has both risks and benefits, consult your doctor if Xeomin® is right for you. Further information on the risks and benefits of Xeomin® can be found in the Consumer Medicine Information (CMI) available from or by calling 0800 822 310. Use strictly as directed. If symptoms continue or you have side effects, see your doctor, pharmacist or health care professional. Common side effects include: Headaches; nausea; tenderness, swelling, redness, numbness or bruising of the skin; dry eye; heavy feeling of eyelid/eyebrow/forehead; face/brow not symmetrical, dropping eyelids/eyebrows. Serious side effects are rare and include allergic reactions. Xeomin is an unfunded medicine, prescription charge will apply. Normal doctor charges will still apply. Copyright© 2023. Pharmacy Retailing NZ Limited t/a Health Care Logistics (HCL) 58 Richard Pearse Drive, Mangere, Auckland 2022. All rights reserved. Xeomin ® and Merz Aesthetics are registered trademarks of Merz Pharma GMbH & Co. KGaA.. Date of preparation: June 2024. TAPS number MR10650

For information about how Merz handles personal data, please see Merz General Data Protection Information Notice at


Denizen’s definitive guide to Auckland’s best yoga studios
Ask an expert: We chat to Sarah Mitchell Weston on all things winter immunity
Considering a natural-looking injectable? This revitalising skin booster should be on your radar